Submitted by comunicaciones on Thu, 07/04/2024 - 07:54
ECBE
DIAGNÓSTICO Y TRATAMIENTO SINTOMÁTICO DE LA PACIENTE CON HEMORRAGIA UTERINA ANORMAL
seccion ECBE
Referencias
Body
  1. Munro MG, Critchley HOD, Fraser IS, Committee the FMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143(3):393-408.
     
  2. Jain V, Chodankar RR, Maybin JA, Critchley HOD. Uterine bleeding: how understanding endometrial physiology underpins menstrual health. Nat Rev Endocrinol. 2022;18(5):290-308.
     
  3. Warring SK, Borah B, Moriarty J, Gullerud R, Lemens MA, Destephano C, et al. The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup. Gynecol Oncol. 1 de enero de 2022;164(1):93-7.
     
  4. Lebduska E, Beshear D, Spataro BM. Abnormal Uterine Bleeding. Med Clin North Am. 1 de marzo de 2023;107(2):235-46.
     
  5. Munro MG, Mast AE, Powers JM, Kouides PA, O’Brien SH, Richards T, et al. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 1 de julio de 2023;229(1):1-9.
     
  6. Munro MG, Critchley HOD, Broder MS, Fraser IS, Disorders for the FWG on M. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynecol Obstet. 2011;113(1):3-13.
     
  7. Singh S, Best C, Dunn S, Leyland N, Wolfman WL. No. 292-Abnormal Uterine Bleeding in Pre-Menopausal Women. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. mayo de 2018;40(5):e391-415.
     
  8. Barros VVD, Hase EA, Salazar CC, Igai AMK, Orsi FA, Margarido PFR. Abnormal uterine bleeding and chronic iron deficiency: Number 11 – December 2022. Rev Bras Ginecol E Obstetrícia RBGO Gynecol Obstet. diciembre de 2022;44(12):1161-8.
     
  9. Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 8 de marzo de 2016;352:i1152.
     
  10. Heavy menstrual bleeding: assessment and management [Internet]. London: National Institute for Health and Care Excellence (NICE); 2021 [citado 23 de marzo de 2023]. (National Institute for Health and Care Excellence: Clinical Guidelines). Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK493300/
     
  11. Duffy A, Ní Bhuinneain M, Burke N, Murphy C. Duffy A, Ní Bhuinneain M, Burke N, National Clinical Practice Guideline: Assessment and Management of Postmenopausal Bleeding. Natl Women Infants Health Programme Inst Obstet Gynaecol. 2022;
     
  12. Torres-Pascual C, Torrell-Vallespín S, Mateos-Pedreño E, García-Serra J. Desarrollo y validación del cuestionario específico de calidad de vida relacionada con la menstruación CVM-22. Rev Cuba Obstet Ginecol. 2019;45(1):48-59.
     
  13. Uterine fibroids | Nature Reviews Disease Primers [Internet]. [citado 29 de marzo de 2024]. Disponible en: https://www.nature.com/articles/nrdp201643
     
  14. Van den Bosch T, Dueholm M, Leone FPG, Valentin L, Rasmussen CK, Votino A, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98.
     
  15. Leone FPG, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR, et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-12.
     
  16. Clark TJ, Stevenson H. Endometrial Polyps and Abnormal Uterine Bleeding (AUB-P): What is the relationship, how are they diagnosed and how are they treated? Best Pract Res Clin Obstet Gynaecol. 1 de abril de 2017;40:89-104.
     
  17. Sheng KK, Lyons SD. To treat or not to treat? An evidence-based practice guide for the management of endometrial polyps. Climacteric. 3 de julio de 2020;23(4):336-42.
     
  18. Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 1 de agosto de 2022;306(2):407-21.
     
  19. ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. mayo de 2018;131(5):e124.
     
  20. Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan T (Terry) J, Sebastianelli A. Guideline No. 390-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 1 de diciembre de 2019;41(12):1789-800.
     
  21. Tanko NM, Linkov F, Bapayeva G, Ukybassova T, Kaiyrlykyzy A, Aimagambetova G, et al. Pipelle Endometrial Biopsy for Abnormal Uterine Bleeding in Daily Clinical Practice: Why the Approach to Patients Should Be Personalized? J Pers Med. 28 de septiembre de 2021;11(10):970.
     
  22. Dueholm M, Hjorth IMD, Secher P, Jørgensen A, Ørtoft G. Structured Hysteroscopic Evaluation of Endometrium in Women With Postmenopausal Bleeding. J Minim Invasive Gynecol. 1 de noviembre de 2015;22(7):1215-24.
     
  23. Telner DE, Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. Can Fam Physician. enero de 2007;53(1):58-64.
     
  24. Giri SK, Nayak BL, Mohapatra J. Thickened Endometrium: When to Intervene? A Clinical Conundrum. J Obstet Gynaecol India. 1 de junio de 2021;71(3):216-25.
     
  25. Van Den Bosch T, Verbakel JY, Valentin L, Wynants L, De Cock B, Pascual MA, et al. Typical ultrasound features of various endometrial pathologies described using International Endometrial Tumor Analysis (IETA) terminology in women with abnormal uterine bleeding. Ultrasound Obstet Gynecol. 2021;57(1):164-72.
     
  26. Dason ES, Maxim M, Sanders A, Papillon-Smith J, Ng D, Chan C, et al. Guideline No. 437: Diagnosis and Management of Adenomyosis. J Obstet Gynaecol Can. 1 de junio de 2023;45(6):417-429.e1.
     
  27. Van den Bosch T, de Bruijn AM, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, et al. Sonographic classification and reporting system for diagnosing adenomyosis. Ultrasound Obstet Gynecol. 2019;53(5):576-82.
     
  28. Vilos GA, Allaire C, Laberge PY, Leyland N, Vilos AG, Murji A, et al. The Management of Uterine Leiomyomas. J Obstet Gynaecol Can. 1 de febrero de 2015;37(2):157-78.
     
  29. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. enero de 2016;214(1):31-44.
     
  30. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 1 de septiembre de 2010;8(9):2063-5.
     
  31. Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemoph Off J World Fed Hemoph. noviembre de 2014;20(6):831-5.
     
  32. Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol. julio de 2013;122(1):176.
     
  33. Jain V, Munro MG, Critchley HOD. Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO Systems 1 and 2. Int J Gynecol Obstet. 2023;162(S2):29-42.
     
  34. OMS. Concentraciones de hemoglobina para diagnosticar la anemia y evaluar su gravedad [Internet]. [citado 11 de febrero de 2024]. Disponible en: https://www.who.int/es/publications/i/item/WHO-NMH-NHD-MNM-11.1
     
  35. Committee Opinion No. 557: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. Obstet Gynecol. abril de 2013;121(4):891-6.
     
  36. Zeybek B, Childress AM, Kilic GS, Phelps JY, Pacheco LD, Carter MA, et al. Management of the Jehovah’s Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach. Obstet Gynecol Surv. agosto de 2016;71(8):488-500.
     
  37. Consenso colombiano de criterios de ingreso a cuidados intensivos: Task force de la Asociación Colombiana de Medicina Crítica y Cuidados Intensivos (AMCI®) | Acta Colombiana de Cuidado Intensivo [Internet]. [citado 29 de marzo de 2024]. Disponible en: https://www.elsevier.es/es-revista-acta-colombiana-cuidado-intensivo-101-avance-resumen-consenso-colombiano-criterios-ingreso-cuidados-S0122726223000277
     
  38. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. abril de 2013;121(4):891-6.
     
  39. James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. octubre de 2011;158(2):124-34.
     
  40. Thorne JG, James PD, Reid RL. Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception? Contraception. 1 de julio de 2018;98(1):1-3.
     
  41. James AH. Heavy menstrual bleeding: work-up and management. Hematol Am Soc Hematol Educ Program. 2 de diciembre de 2016;2016(1):236-42.
     
  42. Critchley HOD, Babayev E, Bulun SE, Clark S, Garcia-Grau I, Gregersen PK, et al. Menstruation: science and society. Am J Obstet Gynecol. noviembre de 2020;223(5):624-64.
     
  43. Kanagasabai PS, Filoche S, Grainger R, Henry C, Hay‐Smith J. Interventions to improve access to care for abnormal uterine bleeding: A systematic scoping review. Int J Gynaecol Obstet. enero de 2023;160(1):38-48.
     
  44. MacGregor B, Munro MG, Lumsden MA. Therapeutic options for the management of abnormal uterine bleeding. Int J Gynecol Obstet. 2023;162(S2):43-57.
     
  45. Dyne PL, Miller TA. The Patient with Non–Pregnancy-Associated Vaginal Bleeding. Emerg Med Clin North Am. 1 de mayo de 2019;37(2):153-64.
     
  46. Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 12 de enero de 2021;5(1):301-25.
     
  47. Azenkot T, Schwarz EB. Special Considerations for Women of Reproductive Age on Anticoagulation. J Gen Intern Med. agosto de 2022;37(11):2803-10.
     
  48. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 31 de marzo de 2016;7:43-52.
     
  49. Samuelson Bannow BT, Chi V, Sochacki P, McCarty OJT, Baldwin MK, Edelman AB. Heavy Menstrual Bleeding in Women on Oral Anticoagulants. Thromb Res. 13 de noviembre de 2020;197:114-9.
     
  50. Eworuke E, Hou L, Zhang R, Wong HL, Waldron P, Anderson A, et al. Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin. Drug Saf. julio de 2021;44(7):753-63.
     
  51. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstet Gynecol. 1 de julio de 2021;138(1):e1-15.
     
  52. Bofill Rodriguez M, Lethaby A, Farquhar C. Non‐steroidal anti‐inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 19 de septiembre de 2019;2019(9):CD000400.
     
  53. Bryant‐Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 15 de abril de 2018;2018(4):CD000249.
     
  54. Sauerbrun-Cutler MT, Alvero R. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture. Fertil Steril. 1 de noviembre de 2019;112(5):799-803.
     
  55. Ashfaq S, Can AS. Danazol. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [citado 29 de marzo de 2024]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK564344/
     
  56. Garnock-Jones KP, Duggan ST. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids. Drugs. octubre de 2017;77(15):1665-75.
     
  57. Finco A, Centini G, Lazzeri L, Zupi E. Surgical management of abnormal uterine bleeding in fertile age women. Womens Health Lond Engl. julio de 2015;11(4):513-25.
     
  58. Doyle DJ, Hendrix JM, Garmon EH. American Society of Anesthesiologists Classification. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [citado 24 de febrero de 2024]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK441940/
     
  59. Björkström LM, Wodlin NB, Nilsson L, Kjølhede P. The Impact of Preoperative Assessment and Planning on the Outcome of Benign Hysterectomy – a Systematic Review. Geburtshilfe Frauenheilkd. febrero de 2021;81(2):200-13.
     
  60. Fink K, Shachar IB, Braun NM. Uterine preservation for advanced pelvic organ prolapse repair: Anatomical results and patient satisfaction. Int Braz J Urol Off J Braz Soc Urol. 2016;42(4):773-8.
     
  61. Pickett CM, Seeratan DD, Mol BWJ, Nieboer TE, Johnson N, Bonestroo T, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 29 de agosto de 2023;8(8):CD003677.
     
  62. Sinha P, Yadav N, Gupta U. Use of Hysteroscopy in Abnormal Uterine Bleeding: An Edge Over Histopathological Examination. J Obstet Gynaecol India. febrero de 2018;68(1):45-50.
     
  63. De Bruijn AM, Ankum WM, Reekers JA, Birnie E, Van Der Kooij SM, Volkers NA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am J Obstet Gynecol. diciembre de 2016;215(6):745.e1-745.e12.
     
  64. Moss J, Christie A. Uterine Artery Embolization for Heavy Menstrual Bleeding. Womens Health. enero de 2016;12(1):71-7.
     
  65. El-Nashar SA, Hopkins MR, Feitoza SS, Pruthi RK, Barnes SA, Gebhart JB, et al. Global endometrial ablation for menorrhagia in women with bleeding disorders. Obstet Gynecol. junio de 2007;109(6):1381-7.
     
  66. Heinonen S, Tyrväinen E, Penttinen J, Saarikoski S, Ruokonen E. Need for critical care in gynaecology: a population-based analysis. Crit Care. 2002;6(4):371.
     
  67. Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, et al. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev. 21 de diciembre de 2021;2021(12):CD002042.
     
  68. Hospital Universitario Nacional. Protocolo para prevención, identificación, manejo y notificación de reacciones adversas transfusionales. 2023.
     
  69. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. junio de 2013;165(6):964-971.e1.
     
  70. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors - PubMed [Internet]. [citado 29 de marzo de 2024]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/12393667/
     
  71. Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. Hematol Am Soc Hematol Educ Program. 30 de noviembre de 2018;2018(1):585-94.
     
  72. Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PloS One. 2015;10(2):e0117383.
     
  73. DiStefano M. Acute Abnormal Uterine Bleeding (AUB), Clinical Pathway. 2 de septiembre de 2021;1:1-9.
     
  74. Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. noviembre de 2017;4(11):e524-33.]
  75. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron deficiency anemia in adults. Am J Med. noviembre de 2008;121(11):943-8.
     
  76. Microcytic Anemia | New England Journal of Medicine [Internet]. [citado 29 de marzo de 2024]. Disponible en: https://www.nejm.org/doi/10.1056/NEJMra1215361?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
     
  77. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet Lond Engl. 27 de febrero de 2016;387(10021):907-16.
     
  78. Goddard AF, James MW, McIntyre AS, Scott BB, on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 1 de octubre de 2011;60(10):1309-16.
     
  79. Skolmowska D, Głąbska D, Kołota A, Guzek D. Effectiveness of Dietary Interventions to Treat Iron-Deficiency Anemia in Women: A Systematic Review of Randomized Controlled Trials. Nutrients. 30 de junio de 2022;14(13):2724.
     
  80. Documento de voluntad anticipada [Internet]. [citado 26 de febrero de 2024]. Disponible en: https://www.minsalud.gov.co/salud/publica/Paginas/documento-de-voluntad-anticipada.aspx
     
  81. Abu-Zaid A, Baradwan S, Badghish E, AlSghan R, Ghazi A, Albouq B, et al. Prophylactic tranexamic acid to reduce blood loss and related morbidities during hysterectomy: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Sci. septiembre de 2022;65(5):406.
     
  82. Beverina I, Razionale G, Ranzini M, Aloni A, Finazzi S, Brando B. Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. Blood Transfus. marzo de 2020;18(2):106-16.
     
  83. Lawson T, Ralph C. Perioperative Jehovah’s Witnesses: a review. Br J Anaesth. noviembre de 2015;115(5):676-87.
     
  84. Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 15 de marzo de 2018;3(3):CD004655.
     
  85. Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. agosto de 2014;166(4):496-513.
     
  86. Ilott I, Rick J, Patterson M, Turgoose C, Lacey A. What is protocol-based care? A concept analysis. J Nurs Manag. 2006;14(7):544-52.
     
  87. Gulwani S. Programming by Examples: Applications, Algorithms, and Ambiguity Resolution. En 2016 [citado 3 de septiembre de 2023]. Disponible en: https://www.microsoft.com/en-us/research/publication/programming-examples-applications-algorithms-ambiguity-resolution/
     
  88. Bacon JL. Abnormal Uterine Bleeding. Obstet Gynecol Clin North Am. junio de 2017;44(2):179-93.
     
  89. Jun GT, Ward J, Morris Z, Clarkson J. Health care process modelling: which method when? Int J Qual Health Care. 1 de junio de 2009;21(3):214-24.
     
  90.  Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 29 de marzo de 2021;372:n71.
     
  91.  Marnach ML, Laughlin-Tommaso SK. Evaluation and Management of Abnormal Uterine Bleeding. Mayo Clin Proc. febrero de 2019;94(2):326-35.
     
  92.  Holesh JE, Bass AN, Lord M. Physiology, Ovulation. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [citado 5 de septiembre de 2023]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK441996/